SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
SCYNEXIS Announces $40.0 Million Private Placement
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
Financial Survey: SCYNEXIS (NASDAQ:SCYX) and KalVista Pharmaceuticals (NASDAQ:KALV)
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS (SCYX) to Release Earnings on Wednesday
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX)
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
3 Stocks Under $10 With the Potential for Massive Gains
3 Dirt-Cheap Drug Developers With Blockbuster Potential
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025
3 Stocks Under $10 With Mammoth Growth Prospects
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Scynexis: Update Following Restructuring Of GSK Deal
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
SCYNEXIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit